X4 Pharmaceuticals (XFOR) Tops Q2 EPS by 46c

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q2 EPS of $0.45, $0.46 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $260 thousand versus the consensus estimate of $15.27 million.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Meta pauses an AI training program that tracks employees' keystrokes after a companywide leak - Insider
• Qualcomm (QCOM) PT Raised to $195 at BofA Securities